Inadequate treatment with HMG-CoA reductase inhibitors by health care providers
- 30 June 1996
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 100 (6) , 605-610
- https://doi.org/10.1016/s0002-9343(96)00011-3
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible MechanismsNew England Journal of Medicine, 1995
- Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management.Circulation, 1994
- Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductaseThe American Journal of Cardiology, 1994
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 1993
- Recent Trends in the Identification and Treatment of High Blood Cholesterol by PhysiciansJAMA, 1993
- Serum Cholesterol Level and Mortality Findings for Men Screened in the Multiple Risk Factor Intervention TrialArchives of internal medicine (1960), 1992
- Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease.Circulation, 1991
- Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein BNew England Journal of Medicine, 1990
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- Incidence of Coronary Heart Disease and Lipoprotein Cholesterol LevelsJAMA, 1986